FDA accepts AstraZeneca's fish oil-based drug Epanova for review

09/19/2013 | Reuters · PharmaTimes (U.K.)

The FDA has accepted AstraZeneca's application to market its fish oil-based drug Epanova as a treatment for severe hypertriglyceridemia. The drug was originally developed by Omthera Pharmaceuticals, which was bought by AstraZeneca this year. A decision is expected by May 5.

View Full Article in:

Reuters · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC